Dupixent approved in the US as the first-ever biologic medicine …
WEBSep 27, 2024 · Dupixent has a proven track record as a first-in-class medicine, providing benefit to the many patients suffering from type 2 inflammatory related diseases such as asthma and atopic dermatitis.
Press Release: Dupixent is the first and only biologic to ... - Sanofi
WEBSep 11, 2005 · Dupixent is the first medication to show significant and robust impacts in this patient population. These latest pivotal results reaffirm the underlying role type-2 inflammation plays in driving multiple skin diseases.
Update on FDA Priority Review of Dupixent® (dupilumab) for the ...
WEBMay 31, 2024 · The Dupixent development program has shown significant clinical benefit and a decrease in type 2 inflammation in Phase 3 trials, establishing that IL-4 and IL-13 are key and central drivers of the type 2 inflammation that plays a major role in multiple related and often co-morbid diseases.
Dupixent® (dupilumab) Approved in the U.S. as the First-ever …
WEBSep 27, 2024 · Dupixent is the leading biologic medicine for all of its FDA-approved indications in new-to-brand prescriptions, and the most prescribed biologic by pulmonologists in the U.S.
Press Room - Sanofi US News
WEBSep 11, 2024 · A Dupixent (dupilumab) confirmatory phase 3 study (LIBERTY-CUPID Study C) met the primary and key secondary endpoints for the investigational treatment of patients with uncontrolled, biologic-naïve CSU receiving background therapy …
Dupixent approved in US for adults with poorly controlled COPD
WEBSep 30, 2024 · The U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with poorly controlled chronic obstructive pulmonary disease (COPD) and high counts of immune cells called eosinophils. Elevated eosinophils are a marker of type 2 inflammation, …
FDA Approves Dupixent for Chronic Obstructive Pulmonary Disease
WEB6 days ago · TUESDAY, Oct. 1, 2024 (HealthDay News) -- The U.S. Food and Drug Administration has approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. The approval was based on results from two pivotal phase 3 trials (BOREAS and ...
Dupixent® late-breaking data from NOTUS confirmatory phase 3 …
WEBMay 20, 2024 · NOTUS results confirm landmark data from the phase 3 BOREAS study and show Dupixent significantly reduced exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled chronic obstructive pulmonary disease (COPD) with evidence of type 2 inflammation
“Strategic market positioning” needed for Ebglyss to rival Dupixent …
WEB6 hours ago · Revenue is expected to keep growing for Dupixent, with GlobalData projecting the drug to earn $23.6bn in annual sales by 2030. Dupixent’s large annual takings are due to it being approved in further inflammatory conditions beyond just atopic dermatitis, including asthma and chronic obstructive pulmonary disease …
Press Release: Dupixent approved in the US as the first-ever …
WEBSep 27, 2024 · The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as an add-on maintenance treatment of adults with inadequately controlled chronic obstructive pulmonary disease (COPD)...